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with already diagnosed SARS-CoV-2 infection 
but also in the majority of anticoagulated pa-
tients who are facing substantial limitations 
in everyday medical care. The current docu-
ment provides practical guidance for antico-
agulation management of both groups during 
the COVID-19 pandemic in Poland. We have an-
alyzed available expert opinions from Europe 
Introduction Severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2) causing 
coronavirus disease 2019 (COVID-19) has cre-
ated an unprecedented challenge for health-
care systems and influenced management of pa-
tients with a broad spectrum of acute or chron-
ic diseases. The COVID-19 pandemic has also 
affected anticoagulation not only in patients 
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AbstrAct
The coronavirus disease 2019 (COVID-19) pandemic affects anticoagulation not only in those infected with 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) but also in most patients who require daily 
anticoagulant therapy and are facing substantial limitations in medical care these days. Concomitant venous 
thromboembolism (VTE), a potential cause of unexplained deaths, has frequently been reported in patients 
with COVID-19, but its management is still challenging due to the complexity between antithrombotic 
therapy and hematological alterations. In the era of COVID-19 pandemic, it is highly recommended for 
patients who require chronic anticoagulation to continue therapy to prevent thromboembolic events. 
To avoid regular and frequent blood tests and unnecessary exposure to SARS-CoV-2 during contacts with 
medical personnel, direct oral anticoagulants should be strongly preferred whenever possible. Current 
evidence is insufficient to recommend routine pharmacological antithrombotic prophylaxis in all hospitalized 
patients with COVID-19. In patients with COVID-19 who are suspected of VTE or in whom the diagnosis is 
confirmed, parenteral therapy with low-molecular-weight heparin should be initiated in the absence of 
contraindications. If heparin-induced thrombocytopenia is suspected, nonheparin anticoagulants should 
be used such as bivalirudin or fondaparinux. In case of confirmed acute pulmonary embolism, treatment 
should be guided by risk stratification as defined in the current guidelines.
Key words
anticoagulation, 
coagulation 
abnormalities, 
coronavirus disease 
2019, prophylaxis, 
venous thrombo-
embolism
E X P E R T  O P I N I O N  A N D  P O S I T I O N  P A P E R
Guidance for anticoagulation management 
in venous thromboembolism during 
the coronavirus disease 2019 pandemic in Poland
An expert opinion of the Section on Pulmonary Circulation of the Polish Cardiac Society
Dariusz A. Kosior1,2, Anetta Undas3, Grzegorz Kopeć4, Tomasz Hryniewiecki5, 
Adam Torbicki6, Tatiana Mularek-Kubzdela7, Jerzy Windyga8, Piotr Pruszczyk9
1  Mossakowski Medical Research Centre Polish Academy of Science, Warsaw, Poland
2 Department of Cardiology and Hypertension with the Electrophysiological Lab, Central Clinical Hospital of the Ministry of the Interior and Administration, Warsaw, Poland
3  Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland
4  Department of Cardiac and Vascular Diseases, John Paul II Hospital, Jagiellonian University Medical College, Kraków, Poland
5 Department of Acquired Cardiac Defect, Institute of Cardiology, Warsaw, Poland
6  Department of Pulmonary Circulation and Thromboembolic Diseases and Cardiology, Centre of Postgraduate Medical Education, European Health Centre, ECZ-Otwock, Poland
7  1st Department of Cardiology, Poznan University of Medical Sciences, Poznań, Poland
8 Department of Hemostasis Disorders and Internal Medicine Laboratory of Hemostasis and Metabolic Diseases Institute of Hematology and Transfusion Medicine, Warsaw, Poland
9 Department of Internal Medicine and Cardiology, Medical University of Warsaw, Warsaw, Poland
E X P E R T  O P I N I O N  A N D  P O S I T I O N  P A P E R  Anticoagulation during the COVID-19 pandemic 643
•	 Switching	from	VKAs	to	DOACs	should	be	
considered whenever feasible. Such a change 
is	especially	indicated	in	patients	on	VKAs	
who have had labile INR in previous weeks 
or are not able to measure INR at home.
•	 When	switching	from	VKAs	to	DOACs,	it	
should be taken into account whether the new 
anticoagulant is available and affordable for 
the patient. Appropriate dosing regimens 
should be used and underdosing should be 
avoided.	The choice	of	dabigatran,	rivaroxa-
ban,	or	apixaban	should	be	left	at the	discre-
tion of the treating physician.
However,	some	patients	should	not	be	treat-
ed with DOACs (TAblE 1).The European Heart 
Rhythm Association recommended that DO-
ACs can be initiated immediately if the INR is 
2	or	less.	If the INR	is	2	to	2.5,	DOACs	can	be	
started immediately or preferably on the next 
day.4	For	INR	greater	than	2.5,	the actual	INR	
value	and	the half-life	of	the VKA	need	to	be	
taken into account to estimate the time when 
the INR value will likely drop to below this 
threshold value (half-life of acenocoumarol is 
8–24	hours,	while	of	warfarin,	36–48	hours).	
However,	according	to	the summary	of	prod-
uct	characteristics,	rivaroxaban	can	be	start-
ed	when	INR	is	3	or	less	(depending	on	the in-
dication),	and	apixaban	and	dabigatran	when	
INR is 2 or less.
•	 It	is	advised	to	reconsider	indications	for	long-
term anticoagulation. In patients with low 
risk	of	thromboembolic	episode,	anticoagula-
tion	should	be	stopped	if,	for	example,	a trig-
gering	factor	was	significant	and	transient,	
such as major surgery or trauma and the pa-
tient was successfully treated for more than 
the recommended	3	months.5
•	 It	is	recommended	that	patients	who	continue	
VKA	anticoagulation	avoid	public	transporta-
tion for blood sampling. The setup of outpa-
tient clinics and patient flow should be mod-
ified in order to limit close personal contact.
and United States regarding anticoagulation in 
the era of COVID-19 and we have considered 
Polish conditions.1-3
Patients without COVID-19 who require anti-
coagulation According to the currently avail-
able	data,	the majority	of	patients	who	receive	
oral anticoagulation in Poland are treated with 
direct	oral	anticoagulants	(DOACs).	However,	
approximately 40% of anticoagulated Polish pa-
tients	still	receive	vitamin	K	antagonists	(VKAs),	
that	is,	warfarin	or	acenocoumarol.	Anticoag-
ulation	with	VKAs	requires	close	cooperation	
between the patient and the managing physi-
cian because regular control of international 
normalized ratio (INR) is vital for an effective 
and safe therapy and dose modification may be 
needed. The COVID-19 pandemic caused specif-
ic	issues	related	to	VKA	therapy.	Ambulatory	
INR measurements result in exposure to SARS-
CoV-2 of both patients and medical personnel 
and	increase	the risk	of	infection.	Moreover,	
regular INR measurements create significant 
workload	for	laboratories,	which	are	current-
ly dealing with limited resources. On the oth-
er	hand,	DOAC	therapy	requires	less	frequent	
blood	testing	to	assess	renal	function,	and	the	
therapy can be predicted based on the initial re-
nal	function,	age,	and	manufacturer	recommen-
dations.	Based	on	the	available	data,	the	follow-
ing guidance should be considered:
•	 When	anticoagulation	is	initiated,	DOACs	
should be preferred after excluding contra-
indications	to	avoid	regular	and	frequent	blood	
tests and unnecessary exposure to SARS-
CoV-2 during contacts with medical personnel.
•	 Available	data	indicate	that	the anticoagu-
lant therapy per se does not increase the risk 
of developing severe COVID-19 in patients in-
fected with SARS-CoV-2.1 All patients who re-
quire	chronic	anticoagulation	should	contin-
ue therapy to prevent life-threatening throm-
boembolic events.
Table 1. Contraindications for switching from warfarin to a direct oral anticoagulant
Switching from warfarin to a DOAC should not be considered in the following situations
• Prosthetic mechanical heart valve
• Moderate to severe mitral stenosis
• Patients requiring a higher INR than the standard INR range of 2–3
• Thrombotic APS, in particular manifesting with arterial thromboembolic, stroke, or myocardial infarction when APS 
test was positive 3 times
• Breastfeeding (in case of pregnancy, heparins are recommended)
• Severe renal impairment with CrCl <15 ml/min (for dabigatran <30 ml/min)
• Use of interacting drugs according to the summary of product characteristics for each DOAC, in particular ritonavir 
and lopinavir, or antiviral drugs which lead to increased anticoagulant effect of DOACs. Experts recommend not using 
rivaroxaban in patients with SARS-CoV-2 infection on these investigational COVID-19 medications1a
a  No significant interactions have been reported with DOACs in subjects taking chloroquine or hydroxychloroquine.
Abbreviations: APS, antiphospholipid syndrome; COVID-19, coronavirus disease 2019; CrCl, creatinine clearance; DOAC, direct oral 
anticoagulant; INR, international normalized ratio; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2
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An  increased rate of positive lupus antico-
agulant has been observed in patients with 
COVID-19.13 It might be suggested that all pa-
tients with COVID-19 in whom antiphospho-
lipid antibodies have been detected should be 
closely monitored and receive thromboprophy-
laxis even without history of any thromboem-
bolism.	Of	note,	there	is	evidence	that	hydroxy-
chloroquine,	used	in	some	patients	with	CO-
VID-19 and often with antiphospholipid syn-
drome	(APS),	displayed	some	antithrombotic	
properties,	documented	especially	in	subjects	
with elevated titers of antiphospholipid anti-
bodies.14 APS diagnostic workup should be re-
peated	after	discharge	and	also	after	3	months	
since the first measurement.
Risk of venous thromboembolism and thrombopro ­
p hylaxis The incidence of venous thromboem-
bolism (VTE) in patients with COVID-19 may be 
up	to	30%	of	infected	patients	managed	in	in-
tensive care units.8 The rate of VTE reported in 
general wards ranges from 5% to 10% of patients 
with COVID-19.15 The most common manifesta-
tion of VTE in patients with COVID-19 is iso-
lated pulmonary embolism (PE).15 -17 Most of pa-
tients with COVID-19 diagnosed with VTE have 
no history of previous VTE episodes.15	Of	note,	
VTE	in	about	30%	of	patients	with	COVID-19	in	
the scenario of viral infection can be asymptom-
atic,	which	increases	the risk	of	death.18,19 The di-
agnosis of VTE in COVID-19 increases mortal-
ity 2.5-fold.19 D-dimer levels should be moni-
tored and a sudden rise of this marker after an 
initial decrease in blood with concomitant re-
spiratory failure might suggest VTE.
Lack of validated criteria for the assessment 
of clinical probability of VTE in patients with 
COVID-19 and significant epidemiologic limi-
tations related to transportation and imaging 
make	the VTE	diagnosis	challenging.	Generally,	
COVID-19 is considered a risk factor for throm-
boembolic complications but does not seem to be 
associated with increased bleeding risk.
In	all	patients	with	COVID-19,	VTE	risk	
should be assessed using a risk assessment mod-
el	validated	for	acutely	ill	medical	patients,	pref-
erably used in a given institution. The VTE risk 
stratification should be repeated along with 
bleeding risk assessment during the course of 
COVID-19. Some experts recommend the Pad-
ua or IMPROVE risk assessment models in pa-
tients	with	mild	COVID-19,	while	the Caprini	
scoring system is recommended for surgical or 
trauma patients suspected of or diagnosed with 
COVID-19.20 Outpatients with mild COVID-19 
should not receive pharmacological thrombo-
prophylaxis,	but	increased	mobility	and	ap-
propriate	hydration,	in	particular	in	the pres-
ence	of	fever	or	vomiting,	should	be	encour-
aged. The current OVID trial will assess whether 
a prophylactic dose of enoxaparin reduces early 
•	 In	experienced	compliant	patients	on	stable	
anticoagulation	with	VKA,	the frequency	of	
INR monitoring may be decreased even to 10 
to	14	weeks;	however,	such	a strategy	might	
be	considered	in	rare	cases	only,	including	lo-
gistic problems with blood draw.
•	 In	patients	who	have	to	continue	VKA	ther-
apy,	it	is	advised	to	control	INR	by	self-test-
ing	or	by	a trained	caregiver	using,	for	exam-
ple,	a CoaguChek	device	(Roche).	Dose	adjust-
ment,	when	needed,	can	be	made	by	phone	by	
the managing physician.
•	 Of	note,	if	DOACs	or	VKAs	cannot	be	used	
safely	or	are	not	available,	low-molecular-
weight heparins (LMWHs) can be consid-
ered as an alternative for patients who re-
quire	long-term	anticoagulation.1 Self-injec-
tions by the patient or drug administration 
by a caregiver are advised.
•	 In	patients	without	SARS-CoV-2	infection,	
the antiplatelet therapy regimen should fol-
low the current guidelines.6
Patients with COVID-19 who require anti-
coagulation  Prothrombotic state in COVID-19  
Coronavirus disease 2019 is associated with sev-
eral hematological alterations.7 Two typical he-
mostatic abnormalities observed in patients with 
COVID-19,	that	is,	increased	D-dimer	levels	and	
mild	thrombocytopenia,	were	reported	in	over	
40%	of	those	with	COVID-19	requiring	hospital-
ization.8	Other	abnormalities	frequently	report-
ed in COVID-19 included prolonged prothrom-
bin	time	(PT)	expressed	also	as	INR,	prolonged	
thrombin	time,	and	shortened	activated	partial	
thromboplastin time (aPTT) typical of acute 
phase reaction.9,10
Prolongation	of	aPTT,	PT,	and	thrombocy-
topenia are common particularly in those pa-
tients in whom clinical course is severe. It has 
been suggested that increased D-dimer concen-
trations and prolonged PT are associated with 
higher mortality in patients with COVID-19.8 
Disseminated intravascular coagulation is ob-
served most often in severe cases of COVID-19 
(about 2% of all hospitalized patients) and in-
dicates	poor	prognosis,	that	is,	90%	mortality.11 
The underlying condition contributing to dissem-
inated intravascular coagulation in COVID-19 
are	bacterial	superinfections,	which	should	be	
treated aggressively. Regular laboratory mon-
itoring	of	platelet	count,	PT,	D-dimer	concen-
trations,	and	fibrinogen	levels	in	patients	with	
COVID-19 is recommended to determine the se-
verity	of	coagulopathy.	Systemic	inflammation,	
coagulation	activation,	and	hypoxemia	are	po-
tential predisposing factors for clot formation.
It remains unclear whether SARS-CoV-2 can 
induce antiphospholipid antibodies. Three cas-
es of thrombosis associated with antiphospho-
lipid	antibodies,	namely	anticardiolipin	and	
anti-β2-glycoprotein	I,	have	been	reported.12 
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Treatment of patients with venous thrombo­
embolism In patients with COVID-19 suspect-
ed	of	VTE	or	in	whom	the diagnosis	is	confirmed,	
parenteral therapy with LMWH should be initi-
ated in the absence of contraindications.1,20 Un-
fractionated heparin should be reserved for pa-
tients with strong indications to its use because 
treatment	with	unfractionated	heparin	requires	
time to achieve therapeutic aPTT and is associ-
ated	with	additional	nurse	exposure	for	frequent	
blood draws.1	At discharge,	DOACs	or	LMWHs	
at recommended dosing regimens should be pre-
ferred to limit contact of patients with healthcare 
workers.1 It should be mentioned that some cli-
nicians use an intermediate or therapeutic dose 
of	LMWH	in	patients	with	COVID-19,	based	on	
the assumption that such strategy not only has 
a higher	preventive	value,	but	it	may	treat	VTE,	
as demonstrated in a small study from China in 
which D-dimer levels higher than 1500 ng/ml 
have a sensitivity of 85% and specificity of 88.5% 
for detecting VTE events in patients with COV-
ID-19.6,7 A decision to use such a strategy should 
be taken on the individual case-by-case basis.
Following recommendations regarding an-
ticoagulation should be considered in patients 
with COVID-19:
•	 When	acute	pulmonary	embolism	is	confirmed,	
treatment should be guided by risk stratifica-
tion as defined in the current European Soci-
ety of Cardiology guidelines.8 Patients with 
hemodynamic instability should receive im-
mediate reperfusion therapy preferably with 
thrombolytics. Hemodynamically stable pa-
tients may be treated with LMWH or a DOAC.
•	 Of	note,	DOACs	may	have	significant	inter-
actions	with	drugs	used	for	COVID-19,	es-
pecially with lopinavir / ritonavir via the in-
hibition	of	cytochrome	P450	3A4	(CYP3A4)	
and	/	or	P-glycoprotein	(P-gp).	In	such	cases,	
the bleeding risk may be elevated and when 
lopinavir / ritonavir is administered DOACs 
should be avoided.
•	 Importantly,	no	major	interactions	have	been	
reported between drugs for COVID-19 and 
heparin. Pharmacotherapy selection should 
include in the decision-making process a pos-
sibility of rapid cardiorespiratory decompen-
sation caused by SARS-CoV-2 infection.
Experts recommend e-consultations in hospi-
tals using pulmonary embolism response teams. 
Experts advocate that catheter-directed thera-
pies of acute PE or insertion of inferior vena cava 
filters should be avoided and reserved only for 
the most critical situations.1 In the case of he-
modynamic	instability	in	high-risk	PE,	accord-
ing to the classification by the European Soci-
ety	of	Cardiology,	systemic	fibrinolysis	is	indi-
cated in patients with COVID-19.1,5,20
This statement will be modified along with 
the development of knowledge and therapeu-
tic measures in the management of COVID-19.
mortality and hospitalizations in symptomatic 
outpatients with COVID-19 compared with pla-
cebo. It has been shown using the Padua mod-
el that 40% of hospitalized patients with CO-
VID-19 are at high risk of VTE.21 Pharmacolog-
ical thromboprophylaxis should be used based 
on the current prevention guidelines. Low-mo-
lecular-weight heparins given subcutaneous-
ly once or twice daily should be considered in 
hospitalized patients with COVID-19 at elevat-
ed risk of VTE (intermediate dose at very high 
VTE risk) unless there are absolute contraindi-
cations and bleeding risk is low-to-moderate. 
All severe and critically ill patients with COV-
ID-19 have a strong indication for VTE prophy-
laxis in the absence of contraindications.20 Cur-
rent evidence is insufficient to recommend rou-
tine pharmacological thromboprophylaxis in all 
hospitalized patients with COVID-19.1 Current 
real-life studies showed the use of thrombopro-
phylaxis in all patients with COVID-19 in the in-
tensive	care	units,	which,	however,	is	associated	
with	the rate	of	VTE	approximately	27%,	includ-
ing half of all the cases were diagnosed with-
in 24 hours of hospital admission.15 The fail-
ure rate of LMWH prophylaxis in patients with 
severe	COVID-19	is	estimated	at about	20%,	
which is a much higher rate as compared with 
1% in most LMWH trials in acutely ill medical 
patients (and similar to the values reported in 
sepsis),	leading	to	a suggestion	that	higher	dos-
es of LMWH should be used.6,19 Even a thera-
peutic dose of LMWH can fail to prevent VTE 
in the intensive care setting.18 An alternative is 
unfractionated heparin given twice daily and 
this anticoagulant is preferred in patients with 
chronic kidney disease stage 4 or 5 unless an-
ti-Xa measurement is available. In pregnant 
women	with	COVID-19,	the assessment	of	VTE	
risk should be performed and pharmacological 
thromboprophylaxis should be considered in 
those	who	are	hospitalized,	especially	if	other	
VTE	risk	factors	are	present,	for	example,	age	
above	35	years,	obesity,	thrombophilia,	histo-
ry of VTE.20 The use of extended thrombopro-
phylaxis in patients with COVID-19 after hos-
pital discharge should be considered if the VTE 
risk stratification indicates persistently elevat-
ed	VTE	risk	due	to,	for	example,	comorbidities	
such	as	active	cancer,	prolonged	immobiliza-
tion,	as	well	as	D-dimer	concentrations	higher	
than twice the upper reference range.1	However,	
there are no specific data available on the effica-
cy and safety of such a strategy. If heparin-in-
duced	thrombocytopenia	is	suspected,	nonhep-
arin anticoagulants—such as bivalirudin over 
fondaparinux—should be used. If bivalirudin 
is	unavailable,	fondaparinux	might	be	consid-
ered.20	Therefore,	it	is	recommended	that	hep-
arin,	particularly	LMWH,	for	the primary	pro-
phylaxis of VTE should be considered in all hos-
pitalized patients with SARS-CoV-2 infection.
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